Deferiprone oral solution

DRUG4 trials

Sponsors

ApoPharma, Chiesi Canada Corp

Conditions

Beta Thalassemia Major AnemiaHealthyIron OverloadPantothenate Kinase-Associated Neurodegeneration

Phase 1

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

CompletedNCT02442310

ApoPharmaHealthy

Start: 2015-05-31End: 2015-07-31Updated: 2016-05-13

Phase 3

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

CompletedNCT01741532

ApoPharmaPantothenate Kinase-Associated Neurodegeneration

Start: 2012-12-13End: 2017-01-11Updated: 2019-07-05

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

CompletedNCT02174848

ApoPharmaPantothenate Kinase-Associated Neurodegeneration

Start: 2014-06-30End: 2018-03-16Updated: 2020-08-25

Phase 4

Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

CompletedNCT03591575

Chiesi Canada CorpBeta Thalassemia Major Anemia, Iron Overload

Start: 2018-11-09End: 2020-09-29Updated: 2024-03-15

Related Papers

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)

HemaSphere2022-06-011 citations

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)

HemaSphere2022-01-011 citations

A Prospective Randomized Multicenter Trial Using Either Deferiprone or Deferasirox after an Early Start of Deferiprone or Placebo in Young Children Newly Diagnosed with Transfusion-Dependent Beta-Thalassemia

Blood2021-11-051 citations

Safety and Efficacy of Early-Start Deferiprone in Infants and Young Children with Beta-Thalassemia (START study)

Blood2021-11-051 citations

Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.

2019-07-01105 citations